GlassScriptPhysician profile
Dalianie Nieves
NPI 1073044517
$12,598.69
in general payments reported to CMS, 2019-2025
55 companies · $3,399 in 2025
The $3,399 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $43.22 · 2021: $1,042 · 2022: $1,286 · 2023: $1,929 · 2024: $4,738 · 2025: $3,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,912 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,912.05 |
| Education | $153.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,236.25 | 2022-2025 | Opdivo, Reblozyl, Breyanzi |
| Abbvie INC. | $866.37 | 2019-2025 | |
| Pbg Puerto Rico LLC | $839.63 | 2020-2025 | |
| Amgen INC. | $763.85 | 2021-2025 | Kyprolis, Xgeva, Blincyto |
| Novartis Pharmaceuticals Corporation | $759.63 | 2021-2025 | |
| Genzyme Corporation | $717.86 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $680.56 | 2023-2025 | Erleada, Darzalex, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $629.70 | 2022-2025 | Enhertu, Calquence, Lynparza |
| Merck Sharp & Dohme LLC | $524.35 | 2023-2025 | Keytruda, Welireg |
| Genentech USA, INC. | $410.22 | 2021-2025 | Polivy, Lunsumio, Columvi |
| Takeda Pharmaceuticals U.S.A., INC. | $397.50 | 2021-2025 | Advate |
| Eisai INC. | $384.12 | 2021-2025 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $350.30 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Incyte Corporation | $346.54 | 2022-2025 | Monjuvi, Jakafi, Pemazyre |
| Adc Therapeutics America, INC. | $326.20 | 2024 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $303.81 | 2023-2025 | Cabometyx |
| Bayer Puerto Rico INC. | $282.68 | 2023-2025 | Nubeqa, Stivarga, Vitrakvi |
| Pfizer INC. | $226.21 | 2021-2025 | |
| Astellas Pharma US INC | $181.76 | 2021-2024 | |
| Gilead Sciences, INC. | $170.06 | 2023-2025 | Trodelvy |
| Beigene USA, INC. | $154.84 | 2021-2025 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $154.25 | 2024-2025 | Libtayo |
| Tempus Ai, INC | $152.66 | 2024-2025 | Xt Cdx |
| Springworks Therapeutics, INC. | $148.15 | 2024-2025 | Ogsiveo |
| Puma Biotechnology, INC. | $129.03 | 2023-2025 | Nerlynx |
| Servier Pharmaceuticals LLC | $127.59 | 2025 | |
| Alexion Pharmaceuticals, INC. | $122.87 | 2024-2025 | Ultomiris |
| Seagen INC. | $114.39 | 2021-2025 | |
| Verity Pharmaceuticals INC. | $99.82 | 2023-2024 | Trelstar, Akynzeo |
| Sobi, INC | $96.16 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $93.68 | 2024-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Array Biopharma INC | $87.33 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Mirati Therapeutics, INC. | $80.00 | 2023-2024 | Krazati |
| Genmab U.S., INC. | $76.16 | 2024-2025 | Epkinly |
| Taiho Oncology, INC. | $67.38 | 2024-2025 | |
| Telix Pharmaceuticals | $49.29 | 2025 | Illuccix |
| Kite Pharma, INC. | $41.76 | 2019 | |
| Glaxosmithkline, LLC. | $40.53 | 2025 | Jemperli, Zejula |
| Caris Mpi, INC. | $37.36 | 2025 | Mi Cancer Seek |
| Adaptive Biotechnologies Corporation | $25.99 | 2024 | Clonoseq |
| Global Blood Therapeutics, INC. | $24.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $23.97 | 2022 | |
| Aveo Pharmaceuticals, INC. | $23.70 | 2024 | |
| Jazz Pharmaceuticals INC. | $22.95 | 2022 | |
| Beone Medicines USA, INC. | $21.07 | 2025 | Brukinsa |
| Tolmar, INC. | $20.66 | 2025 | Rubraca, Eligard |
| Pharmaand Gmbh | $20.66 | 2025 | Rubraca |
| Morphosys, US INC. | $20.36 | 2022 | |
| Blueprint Medicines Corporation | $20.11 | 2024 | Ayvakit |
| Deciphera Pharmaceuticals INC. | $19.95 | 2025 | Qinlock, Romvimza |
| Sun Pharmaceutical Industries INC. | $18.43 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $18.25 | 2024 | Onivyde, Somatuline Depot |
| Stemline Therapeutics INC. | $18.20 | 2025 | Orserdu |
| Fennec Pharmaceuticals, INC. | $16.70 | 2024 | Pedmark |
| Bayer Healthcare Pharmaceuticals INC. | $12.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dalianie Nieves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.